Key regions: Australia, Japan, United States, Germany, Europe
The demand for Anti-Coagulants in Vietnam has been increasing steadily over the past few years.
Customer preferences: Vietnamese customers are becoming more health-conscious and are seeking preventive measures to avoid health complications. The aging population in Vietnam is also contributing to the growing demand for Anti-Coagulants. Additionally, there is a rising prevalence of lifestyle diseases such as diabetes and heart diseases, which require Anti-Coagulants as a part of their treatment.
Trends in the market: The Anti-Coagulants market in Vietnam is witnessing a shift towards the use of newer oral anticoagulants (NOACs) from traditional anticoagulants such as warfarin. This is due to the advantages of NOACs, such as a lower risk of bleeding and fewer drug interactions. The increasing availability of NOACs in Vietnam is also contributing to the growth of the Anti-Coagulants market.
Local special circumstances: Vietnam has a large population and a growing middle class, which is driving the demand for better healthcare services. However, the healthcare infrastructure in Vietnam is still developing, and there is a shortage of skilled healthcare professionals. This is a challenge for the Anti-Coagulants market as patients require proper monitoring and dosing adjustments.
Underlying macroeconomic factors: Vietnam's economy has been growing steadily, and the government is investing in healthcare infrastructure to improve the quality of healthcare services. The government has also implemented policies to encourage the production of generic drugs, which has led to a reduction in drug prices, making healthcare more affordable for the population. This has contributed to the growth of the Anti-Coagulants market in Vietnam.Overall, the Anti-Coagulants market in Vietnam is expected to continue to grow in the coming years, driven by the increasing demand for preventive healthcare measures, the rising prevalence of lifestyle diseases, and the shift towards the use of NOACs. However, the shortage of skilled healthcare professionals and the need for proper monitoring and dosing adjustments remain challenges for the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
